Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results
Q3 2024 marks highest ever in-market quarterly sales performance and fourth consecutive quarter of strong sales performanceLund, Sweden, October 17, 2024, Hansa Biopharma today announced its interim report for January-September and third quarter 2024 financial results. Søren Tulstrup, President and CEO, Hansa Biopharma said, “The third quarter of 2024 marks the highest ever IDEFIRIX[®] sales performance to date, resulting in four consecutive quarters of strong sales performance. The launch of IDEFIRIX in Europe continues to advance with adoption in international organ allocation systems